185 related articles for article (PubMed ID: 17931371)
21. N-terminal myristoylation-dependent masking of neutralizing epitopes in the preS1 attachment site of hepatitis B virus.
Bremer CM; Sominskaya I; Skrastina D; Pumpens P; El Wahed AA; Beutling U; Frank R; Fritz HJ; Hunsmann G; Gerlich WH; Glebe D
J Hepatol; 2011 Jul; 55(1):29-37. PubMed ID: 21145866
[TBL] [Abstract][Full Text] [Related]
22. What is the role of serology for the study of chronic hepatitis B virus infection in the age of molecular biology?
Galli C; Orlandini E; Penzo L; Badiale R; Caltran G; Valverde S; Gessoni G
J Med Virol; 2008 Jun; 80(6):974-9. PubMed ID: 18428144
[TBL] [Abstract][Full Text] [Related]
23. Detection of hepatitis B virus PreS1 antigen using a time-resolved fluoroimmunoassay.
Hu Z; Li M; Huang B; Liu J; Yu L; Chen G
J Immunoassay Immunochem; 2012; 33(2):156-65. PubMed ID: 22471606
[TBL] [Abstract][Full Text] [Related]
24. [A study of the causes of poor antiviral responses in male chronic hepatitis B patients treated with recombinant interferon-alpha].
Mao QG; Liu DL; Zhang MX; Feng XR; Hou JL
Zhonghua Gan Zang Bing Za Zhi; 2005 Jan; 13(1):24-6. PubMed ID: 15670486
[TBL] [Abstract][Full Text] [Related]
25. Alterations of leptin during IFN-alpha therapy in patients with chronic viral hepatitis.
Zografos TA; Rigopoulou EI; Liaskos C; Togousidis E; Zachou K; Gatselis N; Germenis A; Dalekos GN
J Hepatol; 2006 May; 44(5):848-55. PubMed ID: 16530290
[TBL] [Abstract][Full Text] [Related]
26. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.
Gish RG; Lok AS; Chang TT; de Man RA; Gadano A; Sollano J; Han KH; Chao YC; Lee SD; Harris M; Yang J; Colonno R; Brett-Smith H
Gastroenterology; 2007 Nov; 133(5):1437-44. PubMed ID: 17983800
[TBL] [Abstract][Full Text] [Related]
27. Expression of the PreS1 peptide of hepatitis B virus and preparation of its polyclonal antibody.
Chen W; Zhang J; Zhang J; Wang D; Li Y; Huang A
Hybridoma (Larchmt); 2011 Dec; 30(6):525-30. PubMed ID: 22149277
[TBL] [Abstract][Full Text] [Related]
28. IgG subclass distribution of hepatitis B surface antigen antibodies induced in children with chronic hepatitis B infection after interferon-alpha therapy.
Gregorek H; Madaliński K; Woynarowski M; Mikolajewicz J; Syczewska M; Socha J
J Infect Dis; 2000 Jun; 181(6):2059-62. PubMed ID: 10837193
[TBL] [Abstract][Full Text] [Related]
29. Diagnosis and management of chronic viral hepatitis: antigens, antibodies and viral genomes.
Chevaliez S; Pawlotsky JM
Best Pract Res Clin Gastroenterol; 2008; 22(6):1031-48. PubMed ID: 19187865
[TBL] [Abstract][Full Text] [Related]
30. [Effect of IL-12 on IFN-gamma and IL-10 produced by peripheral blood mononuclear cells in patients with chronic hepatitis B virus infection during IFN-alpha treatment].
Wang S; Lin Y; Ma W; Zhang B; Qi S; Lan F
Zhonghua Gan Zang Bing Za Zhi; 2002 Apr; 10(2):116-9. PubMed ID: 11983129
[TBL] [Abstract][Full Text] [Related]
31. [Chronic hepatitis B virus (HBV) infection: usefulness of the combination of HBeAg and ALT determination to predict a high HBV-DNA level and therefore the necessity of referral to a specialist for possible antiviral treatment].
Veldhuijzen IK; Mostert MC; Niesters HG; Richardus JH; de Man RA
Ned Tijdschr Geneeskd; 2008 Jun; 152(25):1426-30. PubMed ID: 18624006
[TBL] [Abstract][Full Text] [Related]
32. [Immunological and virological efficacy against HBV chronic infection of the therapeutic vaccine composed of HBV core plus PreS1 in HBV transgenic mice].
Li MZ; Chen XC; Zhou BP; Le XH; Xu LM; Wang HS
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2003 Sep; 17(3):277-9. PubMed ID: 15340577
[TBL] [Abstract][Full Text] [Related]
33. No significant differences in histology and response to interferon treatment in hepatitis B carriers of genotypes C and recombinant B.
Luo K; He H; Liu Z; Zhu Y; Mao Q; Liang W
J Viral Hepat; 2007 Jun; 14(6):419-25. PubMed ID: 17501763
[TBL] [Abstract][Full Text] [Related]
34. Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels.
Tseng TC; Liu CJ; Wang CC; Chen PJ; Lai MY; Chen DS; Kao JH
Antivir Ther; 2009; 14(2):203-10. PubMed ID: 19430095
[TBL] [Abstract][Full Text] [Related]
35. Long-term lamivudine treatment of children with chronic hepatitis B: durability of therapeutic responses and safety.
Jonas MM; Little NR; Gardner SD;
J Viral Hepat; 2008 Jan; 15(1):20-7. PubMed ID: 18088241
[TBL] [Abstract][Full Text] [Related]
36. [Screening and diagnosis of hepatitis B and C].
Chevaliez S; Pawlotsky JM
Rev Prat; 2005 Mar; 55(6):615-23. PubMed ID: 15913113
[TBL] [Abstract][Full Text] [Related]
37. Natural history of chronic hepatitis B virus infection and long-term outcome under treatment.
Liaw YF
Liver Int; 2009 Jan; 29 Suppl 1():100-7. PubMed ID: 19207972
[TBL] [Abstract][Full Text] [Related]
38. [Comparison of lamivudine-induced HBsAg loss rate according to age in children with chronic hepatitis B].
Kim JM; Choe BH; Chu MA; Cho SM
Korean J Hepatol; 2009 Jun; 15(2):168-78. PubMed ID: 19581769
[TBL] [Abstract][Full Text] [Related]
39. Hepatitis B virus and hepatitis C virus dual infection among patients with chronic liver disease.
Saravanan S; Velu V; Nandakumar S; Madhavan V; Shanmugasundaram U; Murugavel KG; Balakrishnan P; Kumarasamy N; Solomon S; Thyagarajan SP
J Microbiol Immunol Infect; 2009 Apr; 42(2):122-8. PubMed ID: 19597643
[TBL] [Abstract][Full Text] [Related]
40. Clinical relevance of HBV DNA load in patients with chronic hepatitis B infection.
Madan K; Batra Y; Jha JK; Kumar S; Kalra N; Paul SB; Singh R; Duttagupta S; Panda SK; Acharya SK
Trop Gastroenterol; 2008; 29(2):84-90. PubMed ID: 18972767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
